【 專門著作 】

1. The impact of pain control on physical and psychiatric functions of cancer patients: a nation-wide survey in Taiwan. Rau KM1, Chen JS2, Wu HB3, Lin SF4, Lai MK5, Chow JM6, Huang ML7, Wang CJ8, Tai CJ9, Hwang WL10, Lu YC11, Chan CH12, Hsieh RK13. Jpn J Clin Oncol. 2015; 45(11):1042-9.
2. Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. Hsieh JC1, Hsu CL2, Ng SH3, Wang CH4, Lee KD5, Lu CH5, Chang YF6, Hsieh RK6, Yeh KH7, Hsiao CH8, Chen SY9, Shiau CY10, Wang HM11. Jpn J Clin Oncol. 2015 Sep;45(9):819-27.
3. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Lim KH1, Chang YC2, Gon-Shen Chen C3, Lin HC2, Wang WT4, Chiang YH2, Cheng HI5, Su NW6, Lin J7, Chang YF6, Chang MC6, Hsieh RK2, Kuo YY8, Chou WC9. Blood Cancer J. 2015 Mar; 5(3): e295.
4. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Chen JS1, Hsu C2, Chiang NJ3, Tsai CS4, Tsou HH5, Huang SF6, Bai LY7, Chang IC6, Shiah HS8, Ho CL9, Yen CJ10, Lee KD11, Chiu CF7, Rau KM12, Yu MS13, Yang Y14, Hsieh RK15, Chang JY16, Shan YS17, Chao Y18, Chen LT19; Taiwan Cooperative Oncology Group. Ann Oncol. 2015 May;26(5):943-9.
5. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Lim KH1, Lin HC2, Chen CG3, Wang WT4, Chang YC2, Chiang YH2, Lin CS4, Su NW5, Su YW5, Lin J6, Chang YF5, Chang MC5, Hsieh RK2, Kuo YY7, Chou WC8. Clin Chim Acta. 2015 Feb 2;440:133-9.
6. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Yu S1, Burke TA, Chan A, Kim HK, Hsieh RK, Hu X, Liang JT, Baños A, Spiteri C, Keefe DM. Support Care Cancer. 2015 Jan;23(1):273-82.